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ABSTRACT 
Schizophrenia is a debilitating psychiatric condition often associated with poor quality of life 
and decreased life expectancy. Lack of progress in improving treatment outcomes has been 
attributed to limited knowledge of the underlying biology, although large-scale genomic 
studies have begun to provide such insight. We report a new genome-wide association study 
of schizophrenia (11,260 cases and 24,542 controls) and through meta-analysis with existing 
data we identify 50 novel associated loci and 145 loci in total. Through integrating genomic 
fine-mapping with brain expression and chromosome conformation data, we identify 
candidate causal genes within 33 loci. We show for the first time that the common variant 
association signal is highly enriched among genes that are under strong selective pressures. 
These findings provide novel insights into the biology and genetic architecture of 
schizophrenia, highlight the importance of mutation intolerant genes and suggest a 
mechanism by which common risk variants persist in the population.   
  
  
Schizophrenia is characterised by psychosis and negative symptoms such as social and 
emotional withdrawal. While onset of psychosis typically does not occur until late 
adolescence or early adult life, there is strong evidence from clinical and epidemiological 
studies that schizophrenia reflects a disturbance of neurodevelopment1.  It confers substantial 
mortality and morbidity, with a mean reduction in life expectancy of 15-30 years2,3. Although 
recovery is possible, most patients have poor social and functional outcomes4. No substantial 
improvements in outcomes have emerged since the advent of antipsychotic medication in the 
mid-20th century, a fact that has been attributed to a lack of knowledge of pathophysiology1.  
Schizophrenia is both highly heritable and polygenic, with risk ascribed to variants spanning 
the full spectrum of population frequencies5-7. The relative contributions of alleles of various 
frequencies is not fully resolved, but recent studies estimate that common alleles, captured by 
genome-wide association study (GWAS) arrays, capture between a third and a half of the 
genetic variance in liability8. There has been a long-standing debate, from an evolutionary 
standpoint, as to how common risk alleles persist in the population, particularly given the 
early mortality and decreased fecundity associated with schizophrenia9. Various hypotheses 
have been proposed including compensatory advantage (balancing selection), whereby 
schizophrenia alleles confer reproductive advantages in particular contexts10,11; hitchhiking, 
whereby risk alleles are maintained by their linkage to positively selected alleles12; or 
contrasting theories that attribute these effects to rare variants and gene-environment 
interaction13. Addressing these competing hypotheses is now tractable given advances from 
recent studies of common genetic variation in schizophrenia.  
The largest published schizophrenia GWAS, that from the Schizophrenia Working Group of 
the Psychiatric Genomics Consortium (PGC), identified 108 genome-wide significant (GWS) 
loci and unequivocally demonstrated the value of increasing sample sizes for discovery in 
schizophrenia genetics research5. Here, we report a large, phenotypically homogeneous GWA 
  
study of schizophrenia which, when combined with previous published data, identifies novel 
facets of genetic architecture and biology, and demonstrates that the evolutionary process of 
background selection can explain the persistence of common risk alleles in the population. 
 
RESULTS 
GWAS and Meta-analysis 
We obtained genome-wide genotype information for schizophrenia cases from the UK (the 
CLOZUK sample), which we combined with control datasets obtained from public 
repositories or through collaboration. The final sample size was of 11,260 cases and 24,542 
controls (5,220 cases and 18,823 controls not in previous schizophrenia GWAS; Methods; 
Supplementary Figure 1; Supplementary Figure 2). At a genome wide level, the 
association statistics indicated that the common variant architecture in the CLOZUK sample 
was highly correlated with an independent sample of 29,415 cases and 40,101 controls from 
the PGC (genetic correlation = 0.954±0.030; p=6.63x10-227) and this was further confirmed 
by polygenic risk score and trend test analyses across the datasets at a range of association p-
value thresholds (Methods and Supplementary Table 1 and 2).  
Meta-analysis of the CLOZUK and the independent PGC dataset, excluding related and 
overlapping samples (total 40,675 cases and 64,643 controls; Supplementary Figure 1), 
identified 179 independent GWS SNPs (p<5x10-8, Supplementary Table 3) mapping to 145 
independent loci (Methods, Figure 1, Supplementary Table 4). The 145 associated loci 
include 93 of those that were GWS in the study of the PGC, the majority of which showed a 
strengthened association (Supplementary Figure 4, Supplementary Table 5). This does not 
imply the remaining 15 PGC loci were false positives, rather this reflects the expected 
inflation of effect sizes for GWS SNPs in incompletely powered studies, and as we 
  
demonstrate, is consistent with all 108 PGC loci representing true positives (see 
Supplementary Note). Of the 52 loci not identified by the PGC, two have been reported as 
genome-wide significant in other studies: the locus at ZEB214 and a locus on chromosome 8 
(38.0-38.3 MB)15.  
In further independent samples (5,662 cases and 154,224 controls); 43 of the 50 GWS index 
SNPs showed the same pattern of allelic association, a level that far surpasses chance 
(p=1.05x10-7). Despite the modest number of cases in these samples, 18 of the 50 index 
alleles reached nominal significance (p<0.05), again implausible by chance (p=1.46x10-11). 
None demonstrated evidence for heterogeneity of effect (Methods, Supplementary Table 
6).  
Mutation intolerant genes  
Recent studies have shown that mutation intolerant genes capture much of the rare variant 
architecture of neurodevelopmental disorders such as autism, intellectual disability and 
developmental delay as well as schizophrenia16-19. Here, we show that for schizophrenia, this 
also holds for common variation. Using gene set analysis in MAGMA20, loss-of-function 
(LoF) intolerant genes (N=3,230) as defined by the Exome Aggregation Consortium 
(ExAC)21 using their gene-level constraint metric pLI ≥ 0.9, were enriched for schizophrenia 
common variant associations in comparison with all other annotated genes (p=4.1x10-16). 
It has been shown that pLI is correlated with gene expression across tissues, including 
brain21, which raises the possibility that the LoF-intolerant gene enrichment in schizophrenia  
may reflect enrichment for signal in genes expressed in the brain. However, LoF-intolerant 
gene set enrichment was robust to the inclusion of “brain expressed” (N=10,360) and “brain 
specific” (N=2,647) gene sets19 as covariates in the analysis (p=1.89x10-10) or to controlling 
for FPKM gene expression values (p=1.03x10-14) in brain22 . 
  
It has been suggested that clustering of risk alleles in mutation intolerant genes is a hallmark 
of early-onset traits under natural selection23,24. However, LoF-intolerant genes are known to 
be enriched for SNPs identified as genome-wide significant in GWAS studies (as listed in the 
NHGRI-EBI GWAS Catalog25) and for broad categories of disorders21. To examine whether 
our finding is a property of polygenic disorders in general, we obtained summary genetic data 
from a neuropsychiatric and non-psychiatric late-onset disorder (Alzheimer’s disease, type-2 
diabetes) and a psychological trait (Neuroticism), each of which has been shown to be under 
minimal selective pressure (see Methods). These other phenotypes show at best a weak 
signal for enrichment of the LoF-intolerant gene set in the MAGMA analysis, not comparable 
to that seen in schizophrenia (Alzheimer’s disease p=0.008, type-2 diabetes p=0.016, 
Neuroticism p=0.066). 
To quantify the contribution of SNPs within LoF-intolerant genes to schizophrenia SNP-
based heritability (h2SNP) we used partitioned LDSR
26 (Supplementary Table 7). Overall, 
genic SNPs account for 64% of h2SNP, a 1.23-fold enrichment proportional to their SNP 
content (p=5.93x10-14). Consistent with the analysis using MAGMA, h2SNP was enriched in 
LoF-intolerant genes (2.01-fold; p=2.78x10-24), which explained 30% of all h2SNP (equating to 
47% of all genic h2SNP). In contrast, genes classed as non LoF-intolerant (pLI<0.9) were 
significantly depleted for h2SNP relative to their SNP content (0.90-fold; p=5.86x10
-3), 
although in absolute terms, SNPs in these genes accounted for 34% of h2SNP. A finer scale 
analysis of the relationship between LoF intolerance scores and enrichment for association 
showed that enrichment is restricted to genes with a pLI score above 0.9, precisely those 
defined as “LoF-intolerant” (Supplementary Figure 5). 
Common risk alleles in regions under background selection 
Our finding that LoF-intolerant genes are enriched for common risk variants raises the 
question of how such alleles are found at common frequencies in the population. While the 
  
contribution of ultra-rare variation in functionally important genes to disorders associated 
with low fecundity can be accounted for by de novo mutation16,19,27, this cannot explain the 
persistence of common alleles. To address this question, we used partitioned LDSR to test the 
relationship between schizophrenia associated alleles and SNP-based signatures of natural 
selection. These included measures of positive selection, background selection, and 
Neanderthal introgression. We examined the heritability of SNPs after thresholding them at 
extreme values for these metrics (top 2%, 1% and 0.5%), including in the baseline model 
annotation sets such as LoF-intolerant genes and genomic regions with extreme linkage 
disequilibrium patterns (Methods).  
We observed strong evidence for schizophrenia h2SNP enrichment in SNPs under strong 
background selection (BGS), which was consistent across all the thresholds we examined 
(Table 1). We also found a significant depletion of h2SNP in SNPs subject to positive selection 
as indexed by the CLR statistic. These two results are mutually consistent, as the calculation 
of the CLR statistic explicitly controls for the effect of BGS28. This suggests that SNPs under 
positive selection, but under weak or no BGS, are depleted for association with 
schizophrenia. No significant relationship between h2SNP and other positive selection or 
Neanderthal introgression measures was found after correction for multiple testing (Table 1). 
An LDSR analysis treating BGS measures as a quantitative trait, rather than as a binary one, 
confirmed that the relationship between BGS and schizophrenia association was not due to 
the imposition of arbitrary thresholds to define strong BGS (p=7.73x10-11). We also note that 
the τc statistic of the LDSC model is significant for BGS, in both binary (p=0.041) and 
quantitative (p=0.023) analyses (Supplementary Table 8). The τc statistic indicates  the 
enrichment of BGS after controlling for all other annotations in the model  (including LoF-
intolerant genes)26, and thus represents a robust and conservative test for the BGS 
enrichment. 
  
The above analyses accounts for a possible confounding relationship between LoF 
intolerance and BGS. To illustrate this more clearly, we binned the BGS intensities into four 
categories of increasing score, and classified SNPs in these bins according to whether they 
are in LoF-intolerant genes, “all other” genes sets and a non-genic set (Supplementary 
Figure 6). Note that the lower boundary of the top bin (BGS intensity > 0.75) corresponds 
approximately to the top 2% BGS threshold in Table 1 and is equivalent to a reduction in 
effective population size estimated at each SNP of 75% or more29. We found significant 
heritability enrichment across all BGS intensity intervals in LoF-intolerant genes that 
increased progressively with higher intensity scores. Importantly, we also found heritability 
enrichment for SNPs under BGS pressure in genes that are not LoF intolerant, restricted to 
the highest BGS intensity bin. Indeed the highest BGS intensity bin in non-LoF genes was 
enriched for heritability at a level roughly equivalent to all LoF genes. These findings point to 
BGS and LoF intolerance as making at least partially independent contributions to heritability 
enrichment in schizophrenia. In contrast, none of the phenotypes we selected on the basis of 
their minimal impact on fecundity (Alzheimer’s disease, type-2 diabetes, neuroticism) 
showed significant BGS enrichment for heritability using either the BGS τc statistic of the 
LDSC model (minimum p > 0.24), or when specifically testing regions of high BGS intensity 
in genes that are tolerant (pLI<0.9) of functional mutations (minimum p > 0.40).   
Systems genomics  
Using MAGMA, we undertook a primary analysis of 134 central nervous system related gene 
sets we have previously shown captures the excess CNV burden in schizophrenia30. In a 
GWAS context, we now show that collectively, this group of gene sets captures a 
disproportionately high fraction of h2SNP (30% of total heritability; enrichment =1.63; p= 
8.57x10-13; 46% of genic heritability; Supplementary Table 8). Of the 134 sets, 54 were 
nominally significant of which 12 survived multiple-testing correction (family-wise error rate 
  
(FWER) p < 0.05, Supplementary Table 9), with no notable association for gene sets such 
as the ARC protein complex and NMDAR protein network, that we have previously 
implicated in rare variant studies30,31. Stepwise conditional analysis, adjusting sequentially for 
the more strongly associated gene sets, resulted in six gene sets that were independently 
associated with schizophrenia (Table 2 and Data Supplement).  These extend from low-
level molecular and sub-cellular processes to broad behavioural phenotypes. The most 
strongly associated gene set is constituted by the targets of the Fragile X Mental Retardation 
Protein (FMRP)32. FMRP is a neuronal RNA-binding protein that interacts with 
polyribosomal mRNAs (the 842 target transcripts of this gene set32) and is thought to act by 
inhibiting translation of target mRNAs, including many transcripts of pre- and post-synaptic 
proteins. The FMRP target set has been shown to be enriched for rare mutational burden in de 
novo exome sequencing studies of autism33 and intellectual disability31. In schizophrenia 
studies, it has also been shown to be nominally significantly enriched for association signal in 
sequencing studies8,31 and in GWAS5,8 but only inconsistently in studies of copy number 
variation30,34. Here we provide the strongest evidence to date for the enrichment of this gene 
set in schizophrenia.  
We highlight another five gene sets that are independently associated with schizophrenia. 
Three of these derive from the Mouse Genome Informatics database35 and relate to 
behavioural and neurophysiological correlates of learning; Abnormal Behaviour 
(MP:0004924), Abnormal Nervous System Electrophysiology (MP:0002272) and Abnormal 
Long Term Potentiation (MP:0002207). We note that two of these gene sets (MP:0004924 
and MP:0002207) were among the five most enriched of 134 gene sets tested in a recent 
schizophrenia CNV analysis30. The remaining two independently associated genes sets were 
voltage-gated calcium channel complexes36 and  the 5-HT2C receptor complex
37. The calcium 
channel finding confirms extensive evidence from common and rare variant studies 
  
implicating calcium channel genes in schizophrenia5,8, including a novel GWAS locus in 
CACNA1D identified in our meta-analysis. Whilst there is less convergent evidence in 
support of the involvement of the 5-HT2C receptor complex in schizophrenia, the fact that we 
identify independent association for this gene set implicates these genes in schizophrenia 
pathophysiology and potentially rejuvenates a previous avenue of 5-HT2C ligand therapeutic 
endeavour in schizophrenia research38.  However we interpret this result with caution given 
the small size of this gene set and the fact that a number of its genes encode synaptic proteins 
that are structurally related to other receptor complexes37, not only 5-HT2C.  
Systems genomics and mutation intolerant genes 
The LoF-intolerant genes and the six conditionally independent (“significant”) CNS-related 
gene sets together account for 39% of schizophrenia SNP-based heritability (p=5.07x10-26), 
equating to 61% of genic heritability (Figure 2A; Supplementary Table 7). This is likely to 
be an underestimation of the true effect of these gene sets since distal non-genic regulatory 
elements (not included in this analysis) will add to the heritability explained by these genes. 
In examining the relationship between the LoF-intolerant and CNS-related gene sets (Figure 
2A), genes belonging to both categories were the most highly enriched (2.6-fold; p=7.90x10-
15), although LoF-intolerant genes that were not annotated to our significant CNS gene sets 
still displayed enrichment for SNP-based heritability (1.74-fold; p=9.77x10-10), while genes 
that were in the significant CNS gene sets but had pLI<0.9 showed more modest enrichment 
(1.39-fold; p= 6.05x10-4). Notably genes outside these categories were depleted in heritability 
relative to their SNP content (enrichment=0.79, p=1.82x10-7). 
This general pattern remained when we focussed on the six significant CNS gene sets 
individually, in that the enrichment in these gene sets derives primarily from their intersection 
with LoF-intolerant genes (Figure 2B). Indeed, only the targets of FMRP showed significant 
enrichment for SNPs in genes that are not LoF intolerant (2.06-fold; p=4.23x10-5).  
  
Data-driven gene set analysis  
To set the systems genomics results in context, and to ensure we were not missing enrichment 
in other gene sets by our hypothesis driven approach, we undertook a purely data-driven 
analysis of a larger comprehensive annotation of gene sets from multiple public databases, 
totalling 6,677 gene sets (Methods, Supplementary Table 10). Six gene sets survived 
FWER correction for the full 6,677 gene sets and showed independence through conditional 
analyses. The LoF-intolerant gene set was the most strongly enriched followed by the two 
most strongly associated functional gene sets we had specified in our hypothesis-driven CNS 
gene set analysis (FMRP targets and MGI Abnormal Behaviour genes). The other three sets 
were calcium ion import (GO:0070509), membrane depolarisation during action potential 
(GO:0086010) and synaptic transmission (GO:0007268). These are highly overlapping with 
the independently associated sets from our primary CNS systems genomic analysis. Indeed if 
we repeat the data-driven comprehensive gene set analysis whilst adjusting for the six 
independently associated CNS gene sets, then the only surviving enrichment term is the LoF-
intolerant genes. These results are consistent with those from CNV analysis30 in that they do 
not support annotations other than those related to CNS function, and demonstrate that 
hypothesis based analysis to maximise power does not substantially impact on the overall 
pattern of results. 
Identifying likely candidates within associated loci  
To identify SNPs and genes which might be causally linked to the GWS associations, we 
used FINEMAP39 to identify credibly causal alleles (those with a cumulative posterior 
probability for a locus of at least 95%) and functionally annotated these alleles using 
ANNOVAR40. This identified 6,105 credible SNPs across 144 GWS loci, excluding the 
MHC region (Methods, Supplementary Table 11). From these, we defined a highly credible 
set of SNPs (N=25) as those that are more likely to explain the associations than all other 
  
SNPs combined (i.e. with a FINEMAP posterior probability greater than 0.5).  Of these, 14 
mapped to genes based on putative functionality (exonic SNPs that cause non-synonymous or 
splice variations or promoter SNPs, n=6) or mapped to regions identified as likely regulatory 
elements (n=8) through chromosome conformation analysis performed in tissue from the 
developing brain using Hi-C41 physical interactions (Methods; Supplementary Table 12). 
One of the implicated alleles is a nonsynonymous variant in the manganese and zinc 
transporter gene SLC39A8. Nonsynonymous variants in this gene have been associated with 
severe neurodevelopmental disorders and deficiencies of SLC39A8 with related impaired 
glycosylation42, highlighting a mechanism of therapeutic potential. 
We also applied Summary-data based Mendelian Randomisation (SMR) analysis43 to the data 
in concert with the dorsolateral prefrontal cortex eQTL data from the CommonMind 
Consortium44 aiming to identify variants that might be causally linked through expression 
changes of specific genes. (Methods, Supplementary Table 13).  After applying a 
conservative threshold (pHEIDI>0.05) which prioritises those co-localised signals due to a 
single causal variant43, we identified 22 candidates at 19 loci with a false discovery rate 
p<0.05.  
In total, the combination of FINEMAP, Hi-C and SMR analyses assigned potentially causal 
genes at 33 GWS loci and implicated a single gene at 27 of these loci. However, the analyses 
intersect for a single gene, ZNF823, indicating the need for more comprehensive functional 
genomic annotations in CNS relevant tissues.     
 
DISCUSSION 
In the largest genetic study of schizophrenia to date, we explore the genomic architecture of, 
and the evolutionary pressures on, common variants associated with the disorder. Our study 
  
provides the first evidence linking common variation in LoF-intolerant genes to risk of 
developing schizophrenia and demonstrates that these genes account for a substantial 
proportion (30%) of schizophrenia SNP-based heritability. Systems genomic analysis 
highlights six gene sets that are independently associated with schizophrenia, and point to 
molecular, physiological and behavioural pathways involved in schizophrenia pathogenesis.  
Given mutation intolerance is due to high selection pressure21,23,24, our finding that 
schizophrenia risk variants that persist at common allele frequencies are enriched in loss-of-
function intolerant genes might appear counter-intuitive. However, novel evidence presented 
here suggests this can be reconciled by background selection (BGS) which is a consequence 
of purifying selection in regions of low recombination45,46. In such regions, recurrent 
selection against deleterious variants causes haplotypes to be removed from the gene pool, 
which reduces genetic diversity in a manner equivalent to a reduction in effective population 
size47. This in turn impairs the efficiency of the selection process, allowing alleles with small 
deleterious effects to rise in frequency by drift48. Such a consequence of purifying selection 
has been shown to be compatible with the genomic architecture of complex human traits49 
and to influence phenotypes in model organisms50. We have explicitly modelled this effect 
(both theoretically and via simulations; Supplementary Note) and provide strong evidence 
for the feasibility of this effect as explanatory for the effect sizes seen for common alleles in 
schizophrenia.  
We did not find enrichment for any measure of positive selection or Neanderthal 
introgression. A recent study explained a negative correlation between schizophrenia 
associations and metrics indicative of a Neanderthal selective sweep as evidence for positive 
selection or polygenic adaptation in schizophrenia12. We do not find any significant 
correlation in our model, which addresses the contribution of BGS, and hence our results are 
not consistent with large contributions of positive selection to the genetic architecture of 
  
schizophrenia (Table 1). Indeed positive selection is not widespread in humans, as reported 
by other studies that explicitly considered or accounted for BGS28,51. Polygenic adaptation, 
the co-occurrence of many subtle allele frequency shifts at loci influencing complex traits52, 
remains an intriguing possibility, but has not been implicated in psychiatric phenotypes, 
including schizophrenia, in recent analyses53,54.  In contrast, BGS has been proposed as a 
mechanism driving Human-Neanderthal incompatibilities, as regions with stronger estimated 
BGS have lower estimated Neanderthal introgression55. We therefore conclude that the bulk 
of the BGS signal we obtain is unlikely to be influenced by positive selection29, challenging 
theories of selective advantage of schizophrenia risk alleles to explain their high population 
frequencies. 
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